汉森制药(002412) - 2020 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2020 was ¥174,351,660.96, representing a decrease of 18.48% compared to ¥213,882,410.43 in the same period last year[7] - Net profit attributable to shareholders was ¥36,943,574.88, down 8.15% from ¥40,221,685.17 year-on-year[7] - Basic earnings per share decreased to ¥0.0734, down 8.14% from ¥0.0799 in the same period last year[7] - Total operating revenue for Q1 2020 was CNY 174,351,660.96, a decrease from CNY 213,882,410.43 in the previous period[42] - Net profit for Q1 2020 was CNY 36,943,574.88, down from CNY 40,221,685.17 in the same period last year, representing a decline of approximately 5.6%[44] - Earnings per share (EPS) for Q1 2020 was CNY 0.0734, compared to CNY 0.0799 in the previous year[45] - The total comprehensive income for Q1 2020 was CNY 49,685,993.22, compared to CNY 41,059,904.38 in the previous year, indicating overall growth in profitability[44] - The total comprehensive income for the first quarter of 2020 was CNY 41,927,805.14, compared to CNY 41,536,352.35 in the same period last year, showing a slight increase[49] Cash Flow - The net cash flow from operating activities was negative at ¥5,782,168.59, a decline of 146.51% compared to ¥12,431,872.48 in the previous year[7] - The net cash flow from operating activities decreased by CNY 18,214,041.07, a decline of 146.51%, attributed to a decrease in sales revenue and customer payments[16] - Cash inflow from operating activities totaled CNY 196,540,859.63, while cash outflow was CNY 202,323,028.22, resulting in a net cash flow deficit[52] - The net cash flow from financing activities increased by CNY 31,440,537.80, a growth of 1067.69%, primarily due to an increase in bank borrowings[17] - The net cash flow from financing activities was CNY 28,495,809.77, a turnaround from a negative cash flow of CNY -2,944,728.03 in the previous year[56] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,941,265,527.88, an increase of 3.10% from ¥1,882,905,804.71 at the end of the previous year[7] - The company's current assets totaled CNY 634,347,892.43 as of March 31, 2020, compared to CNY 593,861,751.70 at the end of 2019, indicating an increase of about 6.8%[32] - The total liabilities of the company were CNY 361,601,845.82 as of March 31, 2020, compared to CNY 352,928,115.87 at the end of 2019, showing a rise of about 2.4%[34] - The company's equity attributable to shareholders increased to CNY 1,579,663,682.06 from CNY 1,529,977,688.84, representing a growth of approximately 3.2%[36] Shareholder Information - The total number of shareholders at the end of the reporting period was 18,952[11] - The largest shareholder, Xinjiang Hansen Equity Investment Management Partnership, holds 40.14% of the company's shares[12] Research and Development - Research and development expenses decreased by CNY 3,722,197.56, a decline of 41.79%, due to reduced R&D investments during the period[16] - Research and development expenses decreased to CNY 5,184,895.94 from CNY 8,907,093.50, suggesting a potential shift in R&D focus or efficiency[43] Other Financial Metrics - The weighted average return on equity was 2.39%, down from 2.91% in the same period last year, a decrease of 0.52%[7] - The company reported non-operating income of ¥671,882.91 from government subsidies, while other non-operating expenses totaled -¥480,505.44[8] - Other comprehensive income increased by CNY 12,742,418.34, a growth of 255.49%, mainly due to the increase in other comprehensive income from Hunan Sanxiang Bank Co., Ltd.[16] - The company reported an investment income of CNY 11,356,632.03, up from CNY 8,972,558.70, indicating improved returns from investments[43] Operational Changes - The company implemented new revenue and leasing standards starting from 2020, with no adjustments made to prior period data[63] - The company has not reported any new product launches or significant market expansion strategies in the current quarter[49]